Leadership & Strategy - Blackstone 总裁兼首席运营官 Jon Gray 正在改变这家私募股权巨头 [1] - Gray 正在倡导新的投资方法 [1] Media & Public Image - Gray 通过病毒式慢跑视频等方式提升公司形象 [1]

“A human face to finance”: How Jon Gray aims to turn Blackstone into a financial megastore for everyday savers https://t.co/V7rshmEfin ...

Exclusive: Blackstone is on the verge of acquiring the Four Seasons hotel in downtown San Francisco, a strong vote of confidence in a hospitality market that was reeling only a couple of years ago https://t.co/UKiNoSIw6F ...

Core Insights - The deal is expected to enhance profitability for the company and achieve a return on investment of approximately 18% by 2029 [1]

ABN Amro Bank says it will acquire NIBC Bank from Blackstone for about €960 million to expand in retail banking in the Netherlands https://t.co/A4sk0Ru4aI ...

Core Viewpoint - The recent financing move by Merck for sac-TMT indicates a strong commitment to the drug's global development, highlighting its potential in the oncology market [1] Group 1: Company Developments - Kolon Biotech (06990) shares rose over 5%, currently trading at 431.2 HKD with a transaction volume of 106 million HKD [1] - Merck has initiated a rare financing action, securing 700 million USD from Blackstone for the global development of sac-TMT, which is a significant ADC drug licensed to Merck by Kolon Biotech in 2022 [1] Group 2: Strategic Insights - Merck retains decision-making and control rights over the development, production, and commercialization of sac-TMT, exchanging future revenue rights for the financing [1] - The collaboration with Blackstone reflects a deep insight into the potential of sac-TMT, aiming to accelerate its global development process [1] Group 3: Clinical Trials and Market Potential - According to Merck's 2025 ASCO investor communication, nine Phase III clinical trial data releases for sac-TMT are expected between 2027 and 2029, which will further validate its market potential [1] - The upcoming data releases are anticipated to solidify sac-TMT's core position in Merck's global pipeline, serving as a "ballast" in its oncology strategy [1]

Core Viewpoint - The recent financing move by Merck for the drug sac-TMT indicates a strong commitment to its development, highlighting its potential in the oncology market and the strategic partnership with Blackstone [1] Company Summary - Kolon Biotech (06990) saw its stock price increase by over 5%, closing at 431.2 HKD with a trading volume of 106 million HKD [1] - Merck has initiated a rare financing round of 700 million USD from Blackstone specifically for the global development of sac-TMT, which Kolon Biotech licensed to Merck in 2022 [1] Industry Summary - The financing reflects Merck's high regard for sac-TMT, which is positioned as a significant ADC (antibody-drug conjugate) in the oncology sector [1] - Key clinical trial data for sac-TMT is expected to be disclosed between 2027 and 2029, which will further validate its market potential and solidify its role in Merck's global pipeline [1] - The collaboration with Blackstone demonstrates a deep insight into sac-TMT's potential, aiming to accelerate its global development process [1]

人事变动 - Blackstone 一位华尔街高级女高管 Kathleen McCarthy Baldwin 计划于年底离职 [1]

Core Viewpoint - Kathleen McCarthy Baldwin, co-head of global real estate, will depart from the company at the end of the year [1] Group 1 - The announcement of Kathleen McCarthy Baldwin's departure indicates a potential shift in leadership within the global real estate sector of the company [1]

Blackstone is leading a £1.5 billion ($2 billion) private credit package for Permira’s buyout of JTC, according to regulatory filings https://t.co/yTqPcztA51 ...